In vitro antibody response to tetanus in the MIMIC™ system is a representative measure of vaccine immunogenicity

被引:26
作者
Byers, Anthony M. [1 ]
Tapia, Tenekua M. [1 ]
Sassano, Emily R. [1 ]
Wittman, Vaughan [1 ]
机构
[1] VaxDesign Corp, Orlando, FL 32826 USA
关键词
Tetanus; Antibody; Human; Vaccine; MIMIC (TM); In vitro; MEMORY B-CELLS; IMMUNITY; VIRUS;
D O I
10.1016/j.biologicals.2009.02.018
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In response to the recurrent failure of animal vaccine protection studies to accurately predict human trial results, we have developed a fully human modular immune in vitro construct (MIMIC (TM)) to serve as a preliminary screen for efficacy testing of potential vaccine formulations. To validate the potential of this approach, we monitored the in vitro-generated tetanus (TT)-specific antibody levels in a cohort of donors before and after receiving tetanus vaccination. Purified CD4_T cell and B cell populations were combined with autologous tetanus vaccine-pulsed dendritic cells to generate specific antibody. Enumeration of TT-specific IgG antibody-secreting cells by ELISPOT displayed a significant increase in the magnitude of this population after vaccination. The relative magnitudes of the in vitro-generated TT-specific antibody response before and after vaccination largely recapitulated the TT-specific IgG serum titer profiles measured in the same individuals. These findings provide evidence that the MIMIC (TM) system can be a rapid and representative in vitro method for measuring vaccine immunogenicity via induction of the memory B cell response. (C) 2009 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:148 / 151
页数:4
相关论文
共 11 条
[1]   Duration of humoral immunity to common viral and vaccine antigens [J].
Amanna, Ian J. ;
Carlson, Nichole E. ;
Slifka, Mark K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (19) :1903-1915
[2]   Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system [J].
Crotty, S ;
Aubert, RD ;
Glidewell, J ;
Ahmed, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 286 (1-2) :111-122
[3]  
ERSHLER WB, 1982, CLIN EXP IMMUNOL, V49, P552
[4]  
Leyendeckers H, 1999, EUR J IMMUNOL, V29, P1406, DOI 10.1002/(SICI)1521-4141(199904)29:04<1406::AID-IMMU1406>3.0.CO
[5]  
2-P
[6]   An in vitro immune response model to determine tetanus toxoid antigen (vaccine) specific immunogenicity: Selection of sensitive assay criteria [J].
Piersma, SJ ;
Leenaars, MPPAM ;
Guzylack-Piriou, L ;
Summerfield, A ;
Hendriksen, CFM ;
McCullough, KC .
VACCINE, 2006, 24 (16) :3076-3083
[7]   Correlates of vaccine-induced immunity [J].
Plotkin, Stanley A. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (03) :401-409
[8]   Efficacy of AIDS vaccine strategies in nonhuman primates [J].
Überla, K .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2005, 194 (04) :201-206
[9]   Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus [J].
Ward, Scott M. ;
Phalora, Prabhjeet ;
Bradshaw, Daniel ;
Leyendeckers, Heike ;
Klenerman, Paul .
JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (06) :813-817
[10]   Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans [J].
Watkins, David I. ;
Burton, Dennis R. ;
Kallas, Esper G. ;
Moore, John P. ;
Koff, Wayne C. .
NATURE MEDICINE, 2008, 14 (06) :617-621